arrow
G

Glenn J. Hanna

Dana-Farber Cancer Institute
H指数:40
被引数:7,034

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

12 Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001

12 法尼基转移酶抑制剂(FTI)达利法尼布与卡博替尼联用治疗肾细胞癌(RCC):FIT-001研究更新后的1a期结果

2026-09-020
OAAI
Summary recommendations from the National Cancer Institute Clinical Trials Planning Meeting on advanced cutaneous squamous cell carcinoma in immunosuppressed patients

国家癌症研究所临床 trials 规划会议关于免疫抑制患者中晚期皮肤鳞状细胞癌的摘要建议

2026-07-210
PRE
Risk-adapted therapy guided by human papillomavirus (HPV) circulating tumor DNA in HPV-positive oropharyngeal cancer (ReACT 1.0): an exploratory phase II trial

人乳头瘤病毒(HPV)循环肿瘤DNA指导下的风险适应性疗法在HPV阳性口咽癌中的探索性II期试验(ReACT 1.0)

2026-05-070
OAAI
A phase 1 clinical trial of the farnesyltransferase inhibitor KO-2806 in combination with cabozantinib in renal cell carcinoma

肾细胞癌中法尼基转移酶抑制剂KO-2806联合卡博赞尼的I期临床试验

2025-10-010
OA
First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer

首次人体评估:使用IL-15超激动剂和CTLA-4阻断治疗晚期头颈癌的记忆样NK细胞

2025-02-143
OA
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma
2024-10-220
OAAI
Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance

Ttmv-hpv DNA在解决口咽癌监测期间不确定发现中的效用

2024-08-014
PRE
Imaging and Biomarker Surveillance for Head and Neck Squamous Cell Carcinoma : A Systematic Review and American Radium Society Appropriate Use Criteria Statement
2024-07-010
OAAI